COVID-19 Resources: Guidance for Chan Researchers

Featured news and announcements

COVID FAQs and new funding opportunities for the period 07/13/21–08/27/21

As COVID-19 spreads across the globe, new research funding opportunities are cropping up, along with questions regarding how COVID-19-related disruptions to research might affect current federal funding. Answers to many of those questions and information on a variety of new funding opportunities is provided by clicking on the related link below:

1. Covid-19 research funding opportunities
2. COVID-19 related research news and policy updates
3. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19
4. Free access and free services for researchers related to COVID-19
5. COVID-19 news by Chan faculty

1. COVID-19 research funding opportunities

Internal COVID-19 Funding Announcements

Non-federal COVID-19 Funding Announcements

NOTE: When applying for external awards, PIs and grant managers should closely review the terms and conditions for potential conflicts. Any questions should be referred to Harvard Chan School SPA. In addition, ALL sponsored proposals must be reviewed by SPA 7 days before the sponsor due date, so please allow appropriate lead time to work with your grant manager prior to the SPA deadline. Additional information on SPA proposal development policies can be found here.

*NEW: PCORI: Broad Funding Announcements, Cycle 2, 2021
Deadline: September 29, 2021
This award funds studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system–level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. Additionally, in continuing to respond to the ongoing COVID-19 pandemic, PCORI has developed a Special Area of Emphasis (SAE) to support innovative, high-impact studies that fit clearly within our core mission of patient-engaged and patient-centered comparative clinical effectiveness research.

*NEW: Connect2Recover Research Competition
Deadline: August 31, 2021
The Connect2Recover Research Competition seeks to identify promising research proposals that will accelerate digital inclusion during the COVID-19 recovery globally. The competition aims to: 1.) improve research focus on digital resiliency and digital inclusion to build back better with broadband for pandemic recovery; 2.) build a global research community of think tanks and academic institutions around digital
inclusion; and 3.) promote knowledge sharing that informs targeted practices to build back better with broadband.

**XPRIZE Health & Pandemic Alliance**
Deadline: Varies by challenge
The XPRIZE Health & Pandemic Alliance is an extension of the existing Pandemic Alliance. This expanded global coalition of businesses, bilateral organizations, government agencies, academic institutions, nonprofits, startups, and foundations will be dedicated to accelerating radical breakthroughs in healthcare, making the health system more resilient and preventing the next pandemic. The Alliance will identify gaps, focus attention on key issues, and catalyze solutions by sharing resources and knowledge, and crowdsourcing innovation. Support is provided through competitions.

**Amazon Web Services: Diagnostic Development Initiative (DDI)**
Deadline: December 31, 2021
This is a two-year, $20M commitment to accelerate research and innovation to advance the collective understanding and detection of COVID-19 and other infectious diseases in order to mitigate current and future outbreaks. AWS is offering AWS Promotional Credits and technical expertise to support the use of AWS services for projects by selected institutions and companies.

**Biogen Foundation: COVID-19 Response**
Deadline: none
The Biogen Foundation has committed $10 million to aid in COVID-19 relief efforts around the world. At this time, the Biogen Foundation’s COVID-19 relief efforts are focused on the following categories: expanding and ensuring access to testing, easing the burden on healthcare systems and healthcare workers, and providing food and necessities for the most vulnerable populations.

**School-Based Healthcare Solutions Network: COVID-19 Student Support Recovery Grant**
Deadline: none
The SBHSN COVID-19 Student Support Recovery Grant is accepting applications from local education agencies (LEAs), charter schools, public schools, and nonpublic and private schools to implement SBHSN’s evidence-based mental healthcare program. The funding will support the placement of licensed mental health professionals on school campuses.

**Start Small LLC/Foundation: Jack Dorsey Public Fund**
Deadline: continuous
Square/Twitter CEO Jack Dorsey’s public fund for global COVID-19 relief. After the pandemic, the focus will shift to girl’s health and education, and UBI. Requests are accepted via the website form.

**COVID-19 Early Treatment Fund (CETF): Outpatient Trials for Repurposed Drugs**
Deadline: None specified
The CETF focuses on funding outpatient clinical trials to repurpose existing drugs for effective COVID-19 treatment. The goal is to rapidly test and implement the use of drugs that have already gone through extensive safety testing and are currently approved and marketed for other indications, as these will be much faster to mass-produce than new drugs. The CETF is funding an array of well-designed outpatient clinical trials in parallel to quickly identify which existing drugs work to treat COVID-19. All funded trials go through a rigorous review process by the organization’s Scientific Advisory Board before being approved. The CETF is interested in trial designs that incorporate next-generation DNA sequencing to identify virus variants and human variants that lead to better or worse outcomes in order to triage patients.
Stop the Spread
Deadline: None
Stop the Spread seeks to address the critical needs of the COVID-19 pandemic in four key ways: research, partnerships, investments, and hyperlocal support. Investments are provided in the form of grant or equity capital to nonprofit and for-profit organizations with novel solutions providers that uniquely address the needs of underserved communities. Organizations interested in exploring collaborations with Stop the Spread may contact them using the online form.

Global Innovation Fund; COVID-19 Response
Deadline: Rolling
The Global Innovation Fund is a non-profit innovation fund that invests in the development, rigorous testing, and scaling of innovations targeted at improving the lives of the world’s poorest people, i.e., those living on less than $5 a day. For-profit companies located anywhere in the world can apply for funding for projects that address COVID-19 in developing countries. GIF supports innovators at all stages of their life cycle, from start-up and pilot-testing through to larger-scale implementation.

The PhRMA Foundation: Valuing Health Equity Challenge Award
Deadline: December 1, 2021
This Challenge Award aims to inspire bold and vital research on how value assessment can better capture evidence regarding diverse populations and drivers of health disparities.

Pfizer: COVID 19 General Research Grants
Deadline: Not indicated
Pfizer is currently accepting COVID-19 general research grant requests that address the following areas:
- Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations
- Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer’s vaccine particularly in specific patient populations
- Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake

King Badouin Foundation: Sofina COVID Solidarity Fund
Deadline: None
The Sofina COVID Solidarity Fund wishes to address the adverse consequences of the global COVID-19 pandemic on two key issues related to Sofina’s focus sectors: specific challenges in healthcare systems and services and the digital gap in education. The Fund will be active for two years and will fund projects which have clearly identified the root causes of a problem in one of the above fields and found a creative and innovative way to solve them in the long term. Selected projects will receive a minimum amount of €500,000. Nonprofit organizations setting up a project in Western Europe, India, or Singapore are eligible to apply.

The Boehringer Ingelheim: IIS Program
Deadline: continuous
This program is offered to all qualified academic and community-based scientists or consortia who are interested in independently proposing and conducting their own research to evaluate potential clinical and non-clinical investigations involving COVID-19 related matters including safety, clinical outcomes, antiviral effects, or antithrombotic benefits.
Deadline: Rolling
For time-sensitive research or additions to research projects that study or support the COVID-19 response. This funding window could support projects that:

- Generate new data to directly inform the COVID-19 response of committed partners
- Evaluate interventions that are expected to improve COVID-19 response or recovery
- Add a module to an existing survey in order to track COVID-19 exposure or response
- Add a treatment arm that may support communities’ resiliency in response to COVID-19
- Anonymize, curate, and share already-collected data quickly so that it can be used for decision-making by the humanitarian community
- Conduct a “downstream survey” that follows up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities’ response to COVID-19

Successful applicants will have a research team or staff that has the necessary experience to study the emergency response. As a result, interdisciplinary teams are encouraged.

Mercatus Center: COVID-19 Response: A Call for Ideas
Deadline: Rolling
The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic, specifically, in the topics of restarting and reopening, institutional challenges, health and science policy, economic and regulatory policy, and monetary policy.

Biogen Foundation: COVID-19 Relief Effort
Deadline: Unspecified (accepting applications)
The Biogen Foundation has committed $10M to aid in COVID-19 relief efforts around the world. At this time, the Biogen Foundation’s COVID-19 relief efforts are focused on the following categories: Expanding and ensuring access to testing; Easing the burden on healthcare systems and healthcare workers; Providing food and necessities for our most vulnerable populations.

Draper Richards Kaplan: Coronavirus Urgent Response Initiative
Deadline: Not specified
This initiative supports ideas that are tackling the most acute and time-critical social problems caused by the Covid-19 pandemic right now. DRK wants to help jumpstart projects that can realistically deploy within 30 days.

Robert Wood Johnson: Pioneering Ideas: Exploring the Future to Build a Culture of Health
Deadline: Continuous
This award seeks ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. While this call for proposals is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, we recognize the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.
Amgen Foundation: COVID-19 Relief Support
Deadline: none
The Amgen Foundation is dedicated to combating this pandemic by working across several fronts to apply their unique strengths in genetics, immunology, and antibody engineering to prevent and treat COVID-19. The Foundation’s COVID-19 Relief Support program is dedicated to supporting patients and communities in the fight against COVID-19. Support is provided in the U.S., including Puerto Rico.

Merck KGaA: Research Grant for Pandemic Preparedness
Deadline: Rolling
This grant seeks proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.

Patient-Centered Outcomes Research Institute: Enhancements to existing Research Projects and Engagement Awards
Deadline: Rolling
PCORI is requesting enhancements to existing Research Projects and Engagement Awards that can be initiated quickly to influence the outcome of the current pandemic and that have some relationship to the original award, using existing teams that are currently funded: COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects; COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards who has funding

Fast Grants: Fast Funding for COVID-19 Science
Deadline: Not announced
These grants are for scientists at an academic institution currently working on a COVID-19 related project and in need of funding. Fast Grants are $10k to $500k and decisions are made in under 48 hours.

Mozzila: COVID-19 Solutions Fund
Deadline: Rolling
The fund will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related

California Institute for Regenerative Medicine (CIRM)
Deadline: Open on a bi-monthly basis.
The CIRM has allocated $5 million in funding for peer-reviewed regenerative medicine and stem cell research that could quickly advance treatments for COVID-19. Support is provided for promising discovery, preclinical, and clinical trial stage projects.

Nellie Mae Education Foundation: Racism is a Virus Too
Deadline: Rolling basis until resources are exhausted
The Nellie Mae Education Foundation created a rapid response fund to respond to the hate crimes and bias against Asian American communities in New England resulting from COVID-19.

Omidyar Network India: Rapid Response Funding for COVID-19
Deadline: Not announced
The Omidyar Network India has announced a rapid response window to fund proposals that support the lower 60% of India’s income distribution in managing and mitigating the challenges that come with Covid-19. Support is provided for initiatives that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19.

Open Road Alliance
Deadline: Not announced
The Open Road Alliance is offering charitable grants to organizations responding directly to COVID-19, with priority given to organizations and activities that have a clear and direct role in ‘flattening the curve’ and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Loans are also available to organizations affected by COVID-19, including those with lost event revenue, those delivering vital community services, and social enterprises.

Bill & Melinda Gates Foundation, Wellcome and Mastercard: COVID-19 Therapeutics Accelerator
Deadline: varies
This initiative speeds development and access to therapies for COVID-19 by coordinate R&D efforts and removing barriers to drug development and scale-up to address the epidemic. Gokhan

2. Federal COVID-19 Funding Announcements

National Institutes of Health:

*NEW: NIH: Impact of Technology and Digital Media (TDM) Exposure/Usage on Child and Adolescent Development (P01 Clinical Trial Optional)
Deadline: November 29, 2021
This opportunity invites submission of Program Project (P01) applications to support integrated, multi-project research programs to create a locus of research examining the pathways by which TDM exposure and usage impact developmental trajectories and health outcomes in early childhood (ages birth-8) or adolescence (ages 9-17). Applicants wishing to address both age groups must do so by submitting separate applications.

NIH: Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) (PAR-20-178)
Deadline: Rolling, 9/14/2020 through 09/14/2021
This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

NIH: Rapid Acceleration of Diagnostics (RADx) Initiative for COVID-19
Deadline: rolling
NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution. Project proposals accepted through online RADx portal.

NIH notices of special interest:
*NEW: NIH: NOSI: Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations
Deadline: October 5, 2021

*NEW: NIH NOSI: Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations
Deadline: October 5, 2021

NIH: Notice of Special Interest (NOSI): Competitive Revision and Administrative Supplements to Existing NICHD HIV Grants and Cooperative Agreements to Understand HIV Health Impacts of COVID-19
Deadline: May 8, 2022

NIH: Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities
Deadline: May 8, 2024

Deadline: May 8, 2024

NIH: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Deadline: through March, 2022

Deadline: through September, 2022

NIH: Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders
Deadline: September 8, 2024

NIH: Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19
Deadline: Sep 8, 2024

NIH: Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)
Deadline: Jan 8, 2023

NIH: Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs
Expiration date: Aug 17, 2024

NIH: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
Expiration date: Dec 16, 2021
NIH: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
Expiration date: Dec 16, 2021

NIH: Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI US4s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation
Deadline: Sep 8, 2024

NIH: Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs
Deadline: Aug 17, 2024

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trials Not Allowed)
Deadline: Feb 28, 2021

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trials Not Allowed)
Deadline: Feb 28, 2021

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trials Not Allowed)
Deadline: Feb 28, 2021

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trials Not Allowed)
Deadline: February 28, 2021

NIH: Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases
Deadline: November 19, 2021

Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection
Deadline: September 8, 2024

NIH: NOSI: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract
Deadline: July 16, 2023

NIH: NOSI: The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)
Deadline: July 6, 2024

Deadline: TBA
NIH: Notice of Special Interest (NOSI): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19) (NOT-AT-20-012)
Deadline: Rolling
To rapidly establish scientific evidence and/or elucidate the mechanism of action of natural product–based remedies for SARS-CoV-2 and COVID-19, NCCIH is encouraging the submission of applications for administrative supplements or competitive revisions of active NCCIH grants.

Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis (NOT-CA-20-054)
Deadline: Not announced
The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-017)
Deadline: Rolling - May 15, 2020 through January 26, 2022
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-016)
Deadline: Rolling - May 15, 2020 through January 25, 2022
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

NGOs

Other federal agencies:

*NEW: CDC Foundation: Partnering for Vaccine Equity - Content Management of Vaccine Resource Hub
Deadline: September 7, 2021
The Partnering for Vaccine Equity: Content Management of Vaccine Resource Hub request for proposals seeks to secure the services of a contractor to solicit, receive, evaluate, tag and upload vaccine-related assets to the Partnering for Vaccine Equity’s Resource Hub that will launch in late August 2021. The CDC Foundation will partner with an organization that has a proven track record of successfully curating high quality public health content. The selected Content Manager will demonstrate extensive knowledge of public health, information science, and the expertise to manage content.

NSF: Predictive Intelligence for Pandemic Prevention Phase I: Development Grants
Deadline: October 1, 2021
Biomedical Advanced Research and Development Authority (BARDA)
Deadline: October 31, 2021
Proposals for diagnostic assay development are solicited under Area of Interest (AOI) 7.7; projects to develop COVID-19 therapeutics, including direct-acting antivirals and host-directed therapeutics, may be submitted under AOI 9.2; and projects to develop and demonstrate innovations and enhancements to pharmaceutical manufacturing platforms to support the development of vaccines and therapeutics for COVID-19 can be submitted under AOI 17.

CDC: Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services to Mitigate Morbidity and Mortality
The overall goals of this operational research are to a) improve mortality and cause of death estimation during the acute emergency phase, b) understand COVID-19 disease transmission, contributing factors and secondary health consequences, c) study the effects of various hand hygiene interventions on mitigating the spread of COVID-19 and d) understand the mental health impact of COVID-19 to reduce associated morbidity and mortality among displaced populations and in emergency settings.

DHHS Administration for Community Living/: Aging and Disability Resource Center/No Wrong Door System Funding Opportunity: Critical Relief Funds for COVID-19 Pandemic Response
Deadline: None specified
The purpose of this emergency FOA is to support capacity and resource allocation at the state, local and territorial level to ensure coordination across agencies and support immediate response to urgent needs resulting from COVID-19. Funding will enable states and territories to support ADRCs in providing critical access functions to those populations most at risk of COVID-19 and mitigate adverse effects resulting from this national pandemic such as social isolation, limited access to nutritional supports and personal care services, etc. Additionally, funds would enable ADRCs to enhance and increase virtual access to services such as utilizing telehealth technologies to engage with health care practitioners and case managers.

NSF: Dear Colleague Letter 20-052 re Corona Virus Proposals
Deadline: varies
NSF is accepting proposals to model, track, inform, educate, and prevent the spread of Coronavirus through its existing funding opportunities. NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Visit NSF, Dear Colleague 20-053 for Coronavirus proposal FAQs and conditions and process for proposal deadline extension.

NSF-Office of Advanced Cyberinfrastructure (OAC), Dear Colleague Letter 20-055
Deadline: varies
OAC is inviting Rapid Response Research (RAPID) funding mechanism proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

DOE: Invitation for COVID-19 Scientific Questions (DOE Resources)
Deadline: Ongoing
The Department encourages scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. Please send research questions that the scientific community may address with DOE resources by email to SC.DCL@science.doe.gov.

Previously Announced NIH Limited Submission Opportunities

3. COVID-19 related research news and policy updates

A few of the provisions in the third COVID-19 relief/response package that might be of particular interest to researchers is below. To read more, please download a section-by-section summary and the legislative text.

- ESI status can be extended due to disruptions From COVID-19. Click here for instructions.
- NIST - $6 million to provide continuity of operations and to conduct research and measurement science to support the testing and treatment of coronavirus. Page 622 of the legislative text.
- NSF - $75 million to support research at molecular, cellular, physiological and ecological levels to better understand coronavirus genetics, modes of action, transmission, virulence, and population dynamics. It is expected that many of these funds will be available through the Rapid Response Research funding mechanism. Read Dear Colleague Letter here. Page 629.
- DOE Office of Science - $99.5 million for costs related to equipment, personnel, and operations to support research on the coronavirus, including support to provide access to user facilities. Page 654.
- EPA S&T - $1.5 million to support research efforts regarding coronavirus – and specifically, research on methods to reduce risks from environmental transmission via contaminated surfaces. Page 713.
- CDC - $4.3 billion to support federal, state, and local public health agencies to prevent, prepare for and respond to the coronavirus. Included in that amount is $500 million for global disease detection and emergency response, $500 million for public health data surveillance and analytics infrastructure modernization, and $300 million for the Infectious Diseases Rapid Response Reserve Fund, which supports immediate response activities during outbreaks. Page 728.
- NIH - The bill includes $945 million to support research and expand on prior research plans, including developing an improved understanding of the prevalence of COVID-19, its transmission and the natural history of infection, and novel approaches to diagnosing the disease and past infection, and developing countermeasures for the prevention and treatment of its various stages. Of this total, $103 million is allocated for NHLBI, $706 million NIAID, $60 million NIBIB, $36 million NCATS, $30 million OD, and $10 million for National Library of Medicine. When combined with the first supplemental, Congress has provided $1.78 billion for NIH research on COVID 19. Page 730.
- BARDA (Biomedical Advanced Research and Development Authority) - At least $3.5 billion to advance construction, manufacturing, and purchase of vaccines and therapeutics to the American people.
- NASA - $60 million to support NASA with resources for operational adjustments associated with mission delays caused by NASA center closures related to coronavirus. Page 628. Also, the package includes a number of health-related authorizations, including the HRSA health professionals and nursing workforce development programs.

4. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19

NIH

- Chart showing the various flexibilities provided for the current and next round of peer review.
Considerations for New and Ongoing Human Subjects Research During the COVID-19 Public Health Emergency under Human Subjects

Coronavirus Update: Guidance for Peer Reviewers

OHRP Guidance on COVID-19 under Human Subjects and Clinical Trials

NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-HL-20-759)

notice on Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19

Virtual NIH Activities for Trainees Outside the NIH

Animal Welfare: COVID-19 Pandemic Contingency Planning for Animal Care and Use Programs

Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding. The page now includes a link to page update history so you can easily see what’s new.

New guidance of flexibilities for awardee, students and conference funding during COVID-19 period

FAQs including new section on Training, Fellowship and Career Development Awards

An FAQ to address questions regarding proposal submission and award management

A lenient late-application policy for those who are unable to meet application deadlines due to the COVID-19 emergency

NIH grant recipients may extend the final budget period of the approved project on active grants one time for up to 12 months without requesting prior approval from NIH

Other Federal Guidance

USAMRAA’s Supplemental Guidance on Administrative Flexibilities for Grants and Cooperative Agreements in Response to COVID-19 Pandemic


Frequently Asked Questions (FAQs) published by The Department of Defense (DoD)

5. Free access and free services for researchers related to COVID-19

NIH VideoCast is a free National Library of Medicine webinar for researchers to learn how to share, discover, and cite COVID-19 data and code in generalist repositories.

NIH Resource to Analyze (COVID-19) Literature: The COVID Portfolio Tool

NIH Office of Portfolio Analysis (OPA) has built a comprehensive listing of (COVID-19) publications, available to the public. The portfolio is updated daily and draws from PubMed resources for citations and abstracts of published biomedical literature.

The COVID-19 High Performance Computing (HPC) Consortium is a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy and IBM to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines.

COVID-19 Collaboration Platform: This platform is a home for RCT protocols that are available for collaboration.

CD2H COVID Case Report Forms and Phenotyping Standards website

The Center for Leading Innovation and Collaboration COVID-19 page
The American Heart Association is working to ensure optimal care for patients with cardiovascular disease who contract coronavirus (COVID-19). Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with COVID-19. Here are helpful resources for health systems, clinics, care providers, patients and the public.

**National Library of Medicine**, through its GenBank® sequence database, is providing the biomedical community free and easy access to genome sequences from the novel coronavirus associated with the recent outbreak of pneumonia in Wuhan, China. The outbreak was declared a global health emergency on January 30, 2020 and GenBank® continues to rapidly release data associated with this outbreak as it comes in and welcomes sequence data submissions as well.

**Internal**: FAS Research Computing has offered to provide enhanced support to Harvard Chan School research related to COVID-19. Examples of support include help with workflow automation to improve efficiency for COVID-19 data analysis, and prioritized assistance for virtual machine requests for hosting a COVID-19 analytic tools website. For more information, please contact the FASRC team via email or attend one of their virtual office hours which are held weekly on Wednesdays from 12 PM to 3 PM.

**Open Research Dataset (CORD-19)** is a resource of over 45,000 scholarly articles, including over 33,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses.

**IBM** has resources to share — like supercomputing power, virus tracking and an AI assistant to answer citizens’ questions.

**LitCovid** is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus.

The National Institute of Allergy and Infectious Diseases (NIAID) has made 2019 SARS-CoV-2 and other Coronavirus strains and reagents available through its BEI Resources Repository.

**The American Journal Experts** are offering free language editing and translation services for articles related to coronavirus disease 2019.

**Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak**, with NIH as a signatory to the statement Wellcome Trust news, January 31, 2020

**The BMJ**: Coronavirus

**Chongqing VIP Information**, a Chinese journal database

**Elsevier**: Novel coronavirus information center

**The Lancet**: COVID-19 resource centre

**New England Journal of Medicine**: free Journal content on coronavirus

Royal Society of Tropical Medicine and Hygiene: Coronavirus free collection

**Springer Nature**, the publisher of Nature: Novel coronavirus (SARS-CoV-2 and COVID-19)

**Wiley Online Library**: COVID-19 resources and news

**WHO**: COVID-19 Course Series - free online courses from OpenWHO

---

### COVID-19 news by Chan faculty

- Check out the School’s updated Coronavirus website, which showcases our researchers’ work on the front lines of the global response to COVID-19:
- Find the latest COVID news by Chan faculty here.